Company Performance - Digi Power X Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.35, representing an earnings surprise of +20.00% [1] - The company posted revenues of $8.11 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.99%, although this was a decline from year-ago revenues of $9.23 million [2] - Over the last four quarters, Digi Power X has surpassed consensus EPS estimates three times [2] Stock Movement and Outlook - Digi Power X shares have increased approximately 74% since the beginning of the year, significantly outperforming the S&P 500's gain of 10% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent price movement [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $7.8 million, and for the current fiscal year, it is -$1.60 on revenues of $33.7 million [7] Industry Context - The Technology Services industry, to which Digi Power X belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Digi Power X's stock performance [5][6]

Company Performance - Actelis Networks, Inc. reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.16, and a decline from earnings of $0.01 per share a year ago, indicating an earnings surprise of -31.25% [1] - The company posted revenues of $0.94 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 5.9%, and a significant drop from year-ago revenues of $3.43 million [2] - Over the last four quarters, Actelis Networks has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Actelis Networks shares have declined approximately 53.1% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $3 million, and for the current fiscal year, it is -$0.44 on revenues of $7.52 million [7] Industry Outlook - The Communication - Components industry, to which Actelis Networks belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - The performance of Actelis Networks may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

分组1 - Fortress Biotech reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of -48.39% [1] - The company posted revenues of $16.41 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 13.66%, compared to $14.9 million in the same quarter last year [2] - Fortress Biotech has surpassed consensus revenue estimates two times over the last four quarters [2] 分组2 - The stock has underperformed the market, losing about 4.7% since the beginning of the year, while the S&P 500 gained 10% [3] - The current consensus EPS estimate for the coming quarter is -$0.24 on revenues of $19.88 million, and for the current fiscal year, it is -$1.29 on revenues of $103.09 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Company Performance - ESS Tech, Inc. reported a quarterly loss of $0.9 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.88, but an improvement from a loss of $1.8 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $2.36 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.75%, but showing significant growth from $0.35 million in the same quarter last year [2] - Over the last four quarters, ESS Tech has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Stock Performance - ESS Tech shares have declined approximately 71.3% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for the stock's immediate price movement [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $1.3 million, and for the current fiscal year, it is -$3.56 on revenues of $6 million [7] - Ahead of the earnings release, the estimate revisions trend for ESS Tech was favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Outlook - The Electronics - Miscellaneous Products industry, to which ESS Tech belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Company Performance - Plus Therapeutics reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.09, and showing improvement from a loss of $0.71 per share a year ago, resulting in an earnings surprise of +88.89% [1] - The company posted revenues of $1.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 18.24%, but showing an increase from year-ago revenues of $1.28 million [2] - Over the last four quarters, Plus has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Plus shares have declined approximately 50.1% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $2.21 million, and for the current fiscal year, it is -$0.55 on revenues of $7.16 million [7] Industry Outlook - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Group 1 - Bolt Biotherapeutics reported a quarterly loss of $4.46 per share, which was better than the Zacks Consensus Estimate of a loss of $6.4, and an improvement from a loss of $11.2 per share a year ago, resulting in an earnings surprise of +30.31% [1] - The company generated revenues of $1.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 73.46%, compared to $1.27 million in the same quarter last year [2] - Over the last four quarters, Bolt Biotherapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2 - The stock has underperformed, losing about 47.5% since the beginning of the year, while the S&P 500 has gained 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$5.70 on revenues of $0.9 million, and for the current fiscal year, it is -$23.00 on revenues of $4.02 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for the stock's performance [8]

Company Performance - Dare Bioscience, Inc. reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of +18.18% [1] - The company has surpassed consensus EPS estimates for the last four quarters, but it reported revenues of -$0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 103.68% [2] - The stock has lost approximately 32.4% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $0.59 million, and for the current fiscal year, it is -$1.99 on revenues of $1.67 million [7] - The estimate revisions trend for Dare Bioscience was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Applied Materials (AMAT) reported quarterly earnings of $2.48 per share, exceeding the Zacks Consensus Estimate of $2.34 per share, and showing an increase from $2.12 per share a year ago, resulting in an earnings surprise of +5.98% [1] - The company achieved revenues of $7.3 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 1.42% and up from $6.78 billion year-over-year [2] - Applied Materials has outperformed the S&P 500, with shares increasing approximately 16.9% since the beginning of the year compared to the S&P 500's gain of 10% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.36 on revenues of $7.31 billion, while for the current fiscal year, the estimate is $9.46 on revenues of $28.8 billion [7] - The estimate revisions trend for Applied Materials was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Electronics - Semiconductors industry, to which Applied Materials belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Applied Materials may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Competitor Insights - Ambarella (AMBA), another company in the same industry, is expected to report quarterly earnings of $0.06 per share, reflecting a year-over-year change of +146.2%, with revenues anticipated to be $90.03 million, up 41.3% from the previous year [9][10]

Core Viewpoint - Canaan reported a quarterly loss of $0.03 per share, outperforming the Zacks Consensus Estimate of a loss of $0.13, and showing improvement from a loss of $0.15 per share a year ago, indicating a significant earnings surprise of +76.92% [1] Financial Performance - Canaan's revenues for the quarter ended June 2025 were $100.21 million, exceeding the Zacks Consensus Estimate by 1.89%, and up from $71.86 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus revenue estimates three times [2] Stock Performance - Canaan shares have declined approximately 60.2% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $135.57 million, and for the current fiscal year, it is -$0.43 on revenues of $486.13 million [7] - The trend of estimate revisions for Canaan was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Financial - Miscellaneous Services industry, to which Canaan belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - HIVE Digital Technologies, another company in the same industry, is expected to report a quarterly loss of $0.08 per share, with revenues projected to be $45.36 million, reflecting a 40.7% increase from the previous year [9]

Group 1: Earnings Performance - Birkenstock reported quarterly earnings of $0.7 per share, exceeding the Zacks Consensus Estimate of $0.67 per share, and up from $0.49 per share a year ago, representing an earnings surprise of +4.48% [1] - Over the last four quarters, the company has surpassed consensus EPS estimates four times [2] - The company posted revenues of $720.54 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.56%, compared to year-ago revenues of $564.76 million [2] Group 2: Stock Performance and Outlook - Birkenstock shares have declined approximately 11.4% since the beginning of the year, while the S&P 500 has gained 10% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.41 on revenues of $606.77 million, and for the current fiscal year, it is $1.86 on revenues of $2.44 billion [7] Group 3: Industry Context - The Shoes and Retail Apparel industry, to which Birkenstock belongs, is currently in the top 40% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Birkenstock's stock performance [5] - Caleres Inc., another company in the same industry, is expected to report quarterly earnings of $0.51 per share, reflecting a year-over-year change of -40% [9]